Novavax, Inc. (NASDAQ:NVAX) Stock Has Consensus Target Price of $14.00 According to Analysts

Novavax, Inc. (NASDAQ:NVAX) has received an average rating of “Hold” from the nine analysts that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $14.00.

A number of research analysts have issued reports on the company. BTIG Research reissued a “buy” rating and issued a $19.00 target price on shares of Novavax in a research note on Thursday, June 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Novavax in a research report on Tuesday, August 4th. Wall Street Zen upgraded Novavax from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Finally, Zacks Research lowered Novavax from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th.

Novavax Stock Down 0.9%

Shares of NASDAQ NVAX opened at $11.22 on Monday. Novavax has a twelve month low of $6.20 and a twelve month high of $13.39. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -7.38 and a beta of 2.44. The company’s fifty day moving average is $9.41 and its 200-day moving average is $9.06.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. The business had revenue of $56.70 million during the quarter, compared to analysts’ expectations of $52.51 million. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The firm’s quarterly revenue was down 76.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.62 EPS. On average, research analysts anticipate that Novavax will post -0.46 EPS for the current fiscal year.

More Novavax News

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax previously benefited from elevated trading activity after the Russia-related health scare, with shares reaching a new 52-week high and trading volume rising above average. However, no government contracts or purchase commitments have been announced. Novavax Surges 20.1 Percent
• Neutral Sentiment: Options activity in NVAX was unusually high, indicating heightened speculative interest and expectations for continued volatility following the recent surge and reversal. Novavax Sees Unusually High Options Volume
• Negative Sentiment: The World Health Organization characterized the risk of a broader plague outbreak as low or “very low.” That guidance removed the immediate catalyst behind the vaccine-sector rally and prompted investors to sell Novavax and other vaccine stocks. Novavax Sinks as WHO Calls Plague Risk Very Low
• Negative Sentiment: Citi’s assessment of vaccine-sector volatility reinforces the view that the recent move was driven largely by headlines and short-term trading rather than fundamentals. Commentary also noted that Novavax’s current product lineup does not directly address plague, making a government-purchase thesis especially speculative. Citi Assesses Vaccine Sector Volatility

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Duncker Streett & Co. Inc. increased its position in shares of Novavax by 917.3% during the first quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 3,825 shares in the last quarter. KBC Group NV lifted its position in Novavax by 34.9% in the 1st quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 1,229 shares in the last quarter. Allworth Financial LP lifted its position in Novavax by 292.5% in the 2nd quarter. Allworth Financial LP now owns 4,353 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 3,244 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in Novavax in the 2nd quarter valued at $42,000. Finally, Principal Financial Group Inc. acquired a new position in Novavax in the 1st quarter worth $83,000. Institutional investors own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on the discovery, development and commercialization of vaccines. The company uses its recombinant protein-based vaccine platform and Matrix-M adjuvant technology to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is its protein-based COVID-19 vaccine, marketed in various regions under the Nuvaxovid or Novavax COVID-19 Vaccine name. The vaccine has been authorized or approved in multiple markets, including the United States, Europe and other international jurisdictions, with availability and regulatory status varying by country.